Mucinous ovarian carcinoma (review)
This review explains how mucinous ovarian cancer differs from other ovarian cancers, why metastases from the bowel must be excluded, and how surgery, fertility preservation and chemotherapy choices are made in a disease with little trial evidence.
Overview
Review covering the epidemiology, pathology and immunohistochemical distinction of primary mucinous ovarian carcinoma from metastatic gastrointestinal tumours, expansile versus infiltrative patterns, molecular features, surgical staging and fertility-sparing surgery, the role of appendicectomy, adjuvant chemotherapy including gastrointestinal-type regimens, and management of advanced disease.
The mucinous ovarian cancer page's emphasis on excluding a gastrointestinal primary, omitting chemotherapy for early expansile tumours, and considering gastrointestinal-type regimens follows this review.
- Randomised evidence is minimal because the disease is rare; the mEOC/GOG 0241 trial closed early.